Latest news

Adalvo is delighted to announce the restart of the DCP procedure for Liraglutide 6mg/ml pre-filled pen, with an estimated approval date anticipated in June 2024. As a generic and bioequivalent...

Adalvo stands in solidarity with the global community on Rare Disease Day, today February 29th, reminding us of the profound challenges faced by millions worldwide battling rare diseases, where access to...

Adalvo is pleased to announce positive progress in the registration process for Mirabegron prolonged-release tablets in European markets. This product has been developed in collaboration with one of our strategic partners,...

Adalvo is pleased to announce that Apremilast 10mg, 20mg, and 30mg film-coated tablets has received its first approval in Europe. Having gained approval in December 2023, this positions Adalvo as the...

Adalvo is delighted to announce the successful DCP approval for Lisdexamfetamine Oral Solution 10mg/ml, developed in close collaboration with one of our strategic partners. This product represents a value-added version of Lisdexamfetamine...

Adalvo is pleased to announce the successful DCP approval for Nintedanib 100mg & 150mg Soft Gel Capsules. This product is developed based on two distinguished reference brands, Ofev and Vargatef. Ofev is indicated for...

Adalvo is proud to announce the successful launch of Desmopressin Sublingual Tablets in France, solidifying our position as the first generic to introduce this innovative medication in the European Union. This accomplishment...

Adalvo is delighted to announce a significant achievement for January 2024, securing a total of 69 Marketing Authorisation Approvals. This success spans across 18 countries, in collaboration with 12 esteemed strategic partners. During this...

On World Cancer Day, Adalvo proudly stands at the forefront of the global battle against cancer. As we commemorate this significant day, we invite you to explore Adalvo's comprehensive Oncology...

As World Cancer Day approaches on Sunday, February 4th, Adalvo reaffirms its commitment to making a meaningful impact in the fight against cancer. With a focus on oncology, Adalvo continues...

Adalvo is pleased to announce the successful DCP submission for Brivaracetam Film-Coated Tablets on Day 1 after the expiry of the Data Exclusivity period, developed in collaboration with one of...

Adalvo is pleased to announce the successful DCP submission for Macitentan 10mg film-coated tablets, developed in collaboration with one of our strategic partners. This product is based on the reference brand Opsumit 10mg film-coated...

Adalvo and ITP are thrilled to announce the successful implementation of SAP S/4HANA, marking the beginning of a promising journey in digital transformation. This collaboration has laid the foundation for a scalable cloud-based...

Adalvo is pleased to announce the successful DCP approval for Vortioxetine Film-Coated Tablets. The product has been developed based on the reference brand Brintellix, which is indicated for treating major depressive episodes and sold...

Adalvo is very proud to announce the successful DCP approval for Pregabalin Prolonged Release Tablets. Pregabalin Prolonged Release Tablets is a backbone medication indicated in the treatment of Neuropathic pain. Having a unique...

Reference is made to the recent notification issued by the European Medicines Agency on Friday, December 15th, recommending the suspension of more than 350generic medicines. The recommendation follows a Good...

Adalvo, in collaboration with Arphio, is proud to introduce Ambrisentan + Tadalafil Film-Coated Tablets (5mg+20mg, 5mg+40mg, 10mg+40mg), an innovative treatment addressing the urgent unmet needs of patients with Pulmonary Arterial Hypertension. In a phase...

Adalvo is pleased to announce that the Pivotal BE Study for Empagliflozin/Metformin Tablets 12.5/1000mg has been successfully completed.  Our product has been developed based on the reference brand Synjardy 12.5mg/1000mg film-coated Tablets, which is indicated for...

We are pleased to announce the successful DCP approval for Apremilast 10mg, 20mg, 30mg film-coated tablets. Our product has been developed based on the reference brand Otezla Film-Coated Tablets, which is indicated in...

Adalvo is pleased to announce that the successful Pivotal BE Study for Cladribine Tablets 10mg has been completed. Committed to innovation and a proactive market strategy, we are working towards becoming among...

Adalvo is pleased to announce that it has entered into a partnership with Juno Pharmaceuticals Canada, to commercialize a number of respiratory and dermatology dossiers. This licensing and supply agreement includes a basket...